Today announced that it offers initiated a new Phase III trial designed to evaluate the efficacy.

‘We believe pimavanserin has an ideal profile to successfully deal with PDP without impairing motor function and, therefore, supplies the potential for an important progress in therapy for patients suffering from this large unmet medical need.’.. ACADIA initiates new pimavanserinContinue reading… Today announced that it offers initiated a new Phase III trial designed to evaluate the efficacy.